Neuphoria Therapeutics (NEUP) Retained Earnings (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Retained Earnings of -$2.1 million for Q1 2026, up 98.78% year-over-year from -$1.0 million in Q1 2025, and up 98.89% quarter-over-quarter from -$186.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Retained Earnings (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Retained Earnings for 6 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 98.78% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$2.1 million (up 98.78% YoY), while the FY2025 annual figure was $200.2 million, up 212.48% from the prior year.
- Retained Earnings rose to -$2.1 million in Q1 2026 per NEUP's latest filing, from -$186.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $203.6 million in Q3 2025 and bottomed at -$186.4 million in Q4 2025.
- Historically, Retained Earnings has averaged -$57.6 million across 5 years, with a median of -$130.5 million in 2022.
- On a YoY basis, Retained Earnings climbed as much as 213.85% in 2025 and fell as far as 4888.13% in 2025.
- Neuphoria Therapeutics' Retained Earnings stood at -$124.1 million in 2022, then decreased by 10.25% to -$136.9 million in 2023, then surged by 97.27% to -$3.7 million in 2024, then sank by 4888.13% to -$186.4 million in 2025, then jumped by 98.89% to -$2.1 million in 2026.
- Business Quant data shows NEUP's Retained Earnings at -$2.1 million in Q1 2026, -$186.4 million in Q4 2025, and $203.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 4.38 Bn |
| 10 | Neuphoria Therapeutics | 21.13 Mn | 1.69 Mn | - | 218.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.07 Mn |
| Dec 31, 2025 | -186.39 Mn |
| Sep 30, 2025 | 203.56 Mn |
| Jun 30, 2025 | 200.19 Mn |
| Mar 31, 2025 | -169.46 Mn |
| Dec 31, 2024 | -3.74 Mn |
| Sep 30, 2024 | -178.80 Mn |
| Jun 30, 2024 | -177.98 Mn |
| Jun 30, 2023 | -136.86 Mn |
| Jun 30, 2022 | -124.13 Mn |
| Jun 30, 2021 | 8.82 Mn |